• Nine abstracts showcasing developments across inflammation & neuroinflammation, psychiatric disease, depression & more! We'll be at Booth No.1818.
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

PK/PD studies

Pharmacokinetic (PK) and Pharmacodynamic (PD) assays are the engine room for Lead Optimisation Drug Discovery.

With our combined years of extensive experience delivering programmes into preclinical development, we understand the need for robust, pharmacologically sensitive, high-throughput, multi-modal in-vivo and ex-vivo endpoints that can be put into context with drug exposure levels.

We can offer almost any dosing route and preclinical species that you might require along with a broad range of behavioural end points and tissue / fluid collection capabilities.

Examples include:


pkThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design